| A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions SG Wicha, C Chen, O Clewe, USH Simonsson Nature communications 8 (1), 2129, 2017 | 97 | 2017 |
| A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro O Clewe, L Aulin, Y Hu, ARM Coates, USH Simonsson Journal of Antimicrobial Chemotherapy 71 (4), 964-974, 2016 | 54 | 2016 |
| Forecasting clinical dose–response from preclinical studies in tuberculosis research: translational predictions with rifampicin SG Wicha, O Clewe, RJ Svensson, SH Gillespie, Y Hu, ARM Coates, ... Clinical Pharmacology & Therapeutics 104 (6), 1208-1218, 2018 | 27 | 2018 |
| A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations O Clewe, SG Wicha, CP de Vogel, JEM de Steenwinkel, USH Simonsson Journal of Antimicrobial Chemotherapy 73 (2), 437-447, 2018 | 23 | 2018 |
| A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells—using rifampicin as an example O Clewe, S Goutelle, JE Conte Jr, USH Simonsson European journal of clinical pharmacology 71 (3), 313-319, 2015 | 21 | 2015 |
| Bilirubin—a potential marker of drug exposure in atazanavir-based antiretroviral therapy D Rekić, O Clewe, D Röshammar, L Flamholc, A Sönnerborg, ... The AAPS journal 13, 598-605, 2011 | 20 | 2011 |
| Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution O Clewe, MO Karlsson, USH Simonsson Journal of Pharmacokinetics and Pharmacodynamics 42, 699-708, 2015 | 10 | 2015 |
| Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions A Faraj, O Clewe, RJ Svensson, GV Mukamolova, MR Barer, ... Scientific Reports 10 (1), 15537, 2020 | 5 | 2020 |
| A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis O Clewe, A Faraj, Y Hu, ARM Coates, USH Simonsson Journal of Pharmacokinetics and Pharmacodynamics 47, 421-430, 2020 | 4 | 2020 |
| A model predicting penetration of rifampicin from plasma to epithelial lining fluid and alveolar cells O Clewe, MO Karlsson, S Goutelle, JE Conte Jr, USH Simonsson Journal of Pharmacokinetics and Pharmacodynamics 40 (S1), S68-S69, 2013 | 1 | 2013 |
| Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide O Clewe, D Rekić, AL Quartino, B Carlsson, M Higashimori, L Wernevik, ... British Journal of Clinical Pharmacology, 2024 | | 2024 |
| Novel Pharmacometric Methods for Informed Tuberculosis Drug Development O Clewe Acta Universitatis Upsaliensis, 2016 | | 2016 |
| Bilirubin-a biomarker of atazanavir exposure in HIV/AIDS patients D Rekić, O Clewe, D Röshammar, L Flamholc, A Sönnerborg, ... | | |
Ulrika SH SimonssonUppsala UniversityVerified email at farmbio.uu.se
